These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 24468818

  • 1. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
    Tur C, Montalban X.
    Mult Scler; 2014 Apr; 20(4):510-1. PubMed ID: 24468818
    [No Abstract] [Full Text] [Related]

  • 2. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 3. Fingolimod and multiple sclerosis: four cautionary tales.
    Bourdette D, Gilden D.
    Neurology; 2012 Nov 06; 79(19):1942-3. PubMed ID: 23035058
    [No Abstract] [Full Text] [Related]

  • 4. Severe relapses under fingolimod treatment prescribed after natalizumab.
    Centonze D, Rossi S, Rinaldi F, Gallo P.
    Neurology; 2012 Nov 06; 79(19):2004-5. PubMed ID: 23035063
    [No Abstract] [Full Text] [Related]

  • 5. New disease-modifying therapies and new challenges for MS.
    Yadav V, Bourdette D.
    Curr Neurol Neurosci Rep; 2012 Oct 06; 12(5):489-91. PubMed ID: 22760478
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes.
    Giovannoni G, Naismith RT.
    Neurology; 2014 Apr 08; 82(14):1196-7. PubMed ID: 24610331
    [Abstract] [Full Text] [Related]

  • 7. [Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].
    Gábor L.
    Ideggyogy Sz; 2014 Mar 30; 67(3-4):141. PubMed ID: 26118259
    [No Abstract] [Full Text] [Related]

  • 8. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
    Ropper AH.
    N Engl J Med; 2012 May 17; 366(20):1938-9. PubMed ID: 22591300
    [No Abstract] [Full Text] [Related]

  • 9. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E, Guareschi A, Vitetta F, Senesi C, Curti E, Montepietra S, Simone AM, Immovilli P, Caniatti L, Tola MR, Pesci I, Montanari E, Sola P, Granella F, Motti L, Ferraro D.
    Curr Med Res Opin; 2014 Sep 17; 30(9):1849-55. PubMed ID: 24831186
    [Abstract] [Full Text] [Related]

  • 10. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
    Crespo C, Izquierdo G, García-Ruiz A, Granell M, Brosa M.
    Neurologia; 2014 May 17; 29(4):210-7. PubMed ID: 24161412
    [Abstract] [Full Text] [Related]

  • 11. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.
    Eur Neurol; 2014 May 17; 72(3-4):173-80. PubMed ID: 25226868
    [Abstract] [Full Text] [Related]

  • 12. Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
    Wipfler P, Harrer A, Pilz G, Oppermann K, Afazel S, Haschke-Becher E, Sellner J, Trinka E, Kraus J.
    Acta Neurol Scand; 2014 Mar 17; 129(3):e12-5. PubMed ID: 24032536
    [Abstract] [Full Text] [Related]

  • 13. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
    Bergvall N, Tambour M, Henriksson F, Fredrikson S.
    J Med Econ; 2013 Mar 17; 16(3):349-57. PubMed ID: 23211038
    [Abstract] [Full Text] [Related]

  • 14. [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].
    Warnke C, Adams O, Hartung HP, Gold R, Hemmer B, Hohlfeld R, Stangel M, Zipp F, Wiendl H, Kieseier BC.
    Nervenarzt; 2011 Oct 17; 82(10):1314-9. PubMed ID: 21656322
    [No Abstract] [Full Text] [Related]

  • 15. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS.
    J Neurol Sci; 2011 Dec 17; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab-associated progressive multifocal leukoencephalopathy.
    Cervera C.
    N Engl J Med; 2012 Aug 30; 367(9):871; author reply 872. PubMed ID: 22931328
    [No Abstract] [Full Text] [Related]

  • 17. Natalizumab-associated progressive multifocal leukoencephalopathy.
    Mancini N, Clementi M, Burioni R.
    N Engl J Med; 2012 Aug 30; 367(9):871-2; author reply 872. PubMed ID: 22931329
    [No Abstract] [Full Text] [Related]

  • 18. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.
    Acta Neurol Scand; 2013 Aug 30; 128(2):e6-e10. PubMed ID: 23336398
    [Abstract] [Full Text] [Related]

  • 19. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Peaureaux D, Pignolet B, Biotti D, Bucciarelli F, Gaina J, Bucur C, Clanet M, Martin-Blondel G, Brassat D.
    Mult Scler; 2015 Apr 30; 21(5):671-2. PubMed ID: 25305251
    [No Abstract] [Full Text] [Related]

  • 20. Natalizumab and fingolimod: insight into their relative efficacies in clinical practice.
    Conway DS, Cohen JA.
    Mult Scler; 2014 Sep 30; 20(10):1280-1. PubMed ID: 25160120
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.